Chemed Corp.

As of October 24, 2025, Chemed Corp. is in a bearish trend, indicated by bearish daily moving averages and Bollinger Bands, with mixed signals from MACD and KST, and has significantly underperformed the S&P 500 with a year-to-date return of -17.59%.

As of October 24, 2025, Chemed Corp. is in a bearish trend with moderate strength, underperforming the S&P 500 significantly, showing a year-to-date return of -17.59% compared to the S&P 500's 15.47%.

As of October 24, 2025, Chemed Corp. is in a bearish trend with moderate strength, indicated by negative daily moving averages and Bollinger Bands, and has significantly underperformed the S&P 500 with a year-to-date return of -17.59% compared to the S&P's 15.47%.

As of October 17, 2025, Chemed Corp. is considered very expensive and overvalued with a P/E ratio of 65 and an EV to EBITDA of 44.10, significantly higher than industry averages, while underperforming the S&P 500 with a year-to-date return of -16.84%.

As of October 17, 2025, Chemed Corp. is considered overvalued with a high P/E ratio of 65, a PEG ratio of 6.80, and a year-to-date return of -16.84%, significantly underperforming its peers and the S&P 500.

As of October 17, 2025, Chemed Corp. is considered very expensive and overvalued, with a P/E ratio of 65 and significant declines in performance, showing a year-to-date return of -16.84% compared to the S&P 500's gain of 13.30%.

As of September 10, 2025, Chemed Corp. is in a bearish trend, supported by negative indicators like a bearish MACD and KST, and has underperformed the S&P 500 with a year-to-date return of -13.51% compared to the S&P 500's 12.22%.

As of July 29, 2025, Chemed Corp. is considered overvalued with a high P/E ratio of 65 and significant underperformance, showing a year-to-date return of -13.51% compared to the S&P 500's 12.22%.

As of June 20, 2025, Chemed Corp's technical outlook is bearish, supported by bearish MACD, Bollinger Bands, and moving averages across various timeframes, despite a mildly bullish signal from Dow Theory on the monthly chart.

As of June 10, 2025, Chemed Corp. is considered overvalued with a P/E ratio of 65, significantly higher than its peers, and despite a YTD return of 4.11%, it has underperformed the S&P 500's 2.44% return.

As of March 2022, the management team of Chemed Corp. includes Mr. Kevin McNamara (CEO), Mr. George Walsh (Independent Chairman), and several independent directors: Mr. Thomas Hutton, Mr. Joel Gemunder, Mr. Patrick Grace, Mr. Walter Krebs, and Dr. Andrea Lindell.

Chemed Corp. operates in the hospital industry, offering hospice and palliative care services through VITAS and plumbing services via Roto-Rooter. As of March 2025, it reported net sales of $647 million and a market cap of approximately $19.62 billion.

As of Jun 18, Chemed Corp. has a market capitalization of $19.62 billion, with net sales of $2.49 billion and a net profit of $308.75 million over the last four quarters.